Asthma is a disease with high incidence and prevalence, and its severe form accounts for approximately 10% of asthmatics. Over the last decade, the increasing knowledge of the mechanisms underlying the disease allowed the development of biological drugs capable of sufficiently control-ling symptoms and reducing the use of systemic steroids. The...
-
2022 (v1)PublicationUploaded on: January 31, 2024
-
2020 (v1)Publication
No description
Uploaded on: February 14, 2024 -
2021 (v1)PublicationAspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report
No description
Uploaded on: February 11, 2024 -
2019 (v1)Publication
Introduction: The precision medicine approach that is now mandatory for severe asthma management includes the use of novel biologic agents blocking specific immunological mechanisms that are responsible for disease phenotypes and endotypes: monoclonal antibodies blocking IgE, IL-5 and IL-4/IL-13 immunological pathways are so far available....
Uploaded on: May 13, 2023 -
2019 (v1)Publication
Background: Omalizumab may modulate airway remodeling in severe asthma. Using forced expiratory volume in 1 second (FEV 1 ) as a surrogate of airway remodeling, we aimed to investigate if an omalizumab add-on in severe allergic asthma may lead to a persistent reversal of airway obstruction and to evaluate the potential biomarkers of airway...
Uploaded on: March 27, 2023 -
2022 (v1)Publication
Introduction: Biologic drugs have dramatically improved severe eosinophilic asthma (SEA) outcomes. Our aim was to evaluate the long-term efficacy of biological therapy in SEA in a real-life setting and to identify the predictors for switching to another biological drug in patients with poor asthma control. The outcomes for efficacy were...
Uploaded on: February 4, 2024 -
2020 (v1)Publication
According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral...
Uploaded on: February 7, 2024 -
2021 (v1)Publication
Background and aims: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients' health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods: Patients >18 years old, referred...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Introduction: There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in...
Uploaded on: April 14, 2023